Table 3 Details of surgery and pathological outcomes of resected patients.

From: Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Variables

Total (n = 27)

Procedure

  Pancreaticoduodenectomy

17 (63.0%)

  Subtotal/distal pancreatectomy

9 (33.3%)

  Total pancreatectomy

1 (3.7%)

Margin status

  R0 resection

22 (81.5%)

  R1 resection

5 (18.5%)

Major vessel resection

  Vein resection

11 (40.7%)

  Artery resection

6 (22.2%)

T stage (AJCC 8th)

  T1

7 (25.9%)

  T2

17 (63.0%)

  T3

3 (11.1%)

  T4

0

N stage (AJCC 8th)

  N0

17 (63.0%)

  N1

8 (29.6%)

  N2

2 (7.4%)

Tumour differentiation

  Well differentiated

4 (14.8%)

  Moderately differentiated

21 (77.8%)

  Poorly differentiated

2 (7.4%)

  1. AJCC American Joint Committee on Cancer.